Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EBIT (2016 - 2025)

Regenxbio has reported EBIT over the past 12 years, most recently at -$57.6 million for Q4 2025.

  • Quarterly results put EBIT at -$57.6 million for Q4 2025, down 12.2% from a year ago — trailing twelve months through Dec 2025 was -$161.2 million (up 30.92% YoY), and the annual figure for FY2025 was -$161.2 million, up 30.92%.
  • EBIT for Q4 2025 was -$57.6 million at Regenxbio, down from -$52.4 million in the prior quarter.
  • Over the last five years, EBIT for RGNX hit a ceiling of $313.6 million in Q4 2021 and a floor of -$73.1 million in Q2 2023.
  • Median EBIT over the past 5 years was -$59.9 million (2022), compared with a mean of -$38.3 million.
  • Peak annual rise in EBIT hit 684.51% in 2021, while the deepest fall reached 511.07% in 2021.
  • Regenxbio's EBIT stood at $313.6 million in 2021, then plummeted by 118.42% to -$57.8 million in 2022, then fell by 10.61% to -$63.9 million in 2023, then grew by 19.62% to -$51.4 million in 2024, then decreased by 12.2% to -$57.6 million in 2025.
  • The last three reported values for EBIT were -$57.6 million (Q4 2025), -$52.4 million (Q3 2025), and -$63.3 million (Q2 2025) per Business Quant data.